Kay Holcombe
Kay Holcombe, MS, retired as Senior Vice President for Science Policy at BIO, the Biotechnology Innovation Organization, held positions in the federal government, on Capitol Hill and in the biotechnology industry. She is on the boards of the Reagan-Udall Foundation, the National Blood Clot Alliance and the Critical Path Institute (C-Path). She joined NORD’s Board of Directors in 2019 and was elected Chair in 2021.
Kay Holcombe, MS, retired as Senior Vice President for Science Policy at BIO, the Biotechnology Innovation Organization, held positions in the federal government, on Capitol Hill and in the biotechnology industry. She is on the boards of the Reagan-Udall Foundation, the National Blood Clot Alliance and the Critical Path Institute (C-Path). She joined NORD’s Board of Directors in 2019 and was elected Chair in 2021.
Articles: Kay Holcombe
NORD’s Breakthrough Summit: Listening to the Rare Disease Patient Voice
USA / The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products Breakthrough Summit on October 18-19th. Ahead of the Summit, the Chair of NORD’s Board of Directors Kay Holcombe explains its significance for cross-stakeholder interaction and learning and why we are entering “a new era for rare disease…
Latest Report
